Professor Helleday presents new data on OXC-101 for psoriasis

At the 13th Uppsala University Symposium on Pharmaceutical Profiling in Drug Discovery and Development, Professor Thomas Helleday presents new data on OXC-101, Oxcia’s mitotic MTH1 inhibitor, in psoriasis – a new indication for the project. OXC-101 is developed for cancer treatment, but in this research Oxcia has found interesting data that indicate potential for treatment of autoimmune disorders. Exploratory research is presently carried out in psoriasis.  There is substantial scientific rational for its use in psoriasis. As in cancer, oxidative stress plays an important role and MTH1 is upregulated in human psoriatic skin.  

The symposium focuses on drug delivery and disposition, therapies, and strategies including Artificial Intelligence and Machine Learning used in drug discovery and development projects (DDD) and takes place on 23 January 2025.

For more information contact:

Ulrika Warpman Berglund, CEO, Oxcia AB (publ)

Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com

Briefly about Oxcia

Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR - the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101  is in early clinical development as novel blood cancer therapy. OXC-201  is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.

More information about Oxcia is available at www.oxcia.com